β-Adrenoceptor blockers in chronic heart failure - A review

British Journal of Clinical Pharmacology

Volumn 44, Issue 2, 1997, Pages 111-118

  Krum, Henry ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Adrenergic; Congestive heart failure; Sympathetic; Adrenoceptor blockers

Indexed keywords

ACEBUTOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; CELIPROLOL; DILEVALOL; LABETALOL; METOPROLOL; NEBIVOLOL; NEUROHORMONE; OXPRENOLOL; PINDOLOL; PRENALTEROL; PROPRANOLOL; XAMOTEROL;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG CHOICE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HOSPITALIZATION; HUMAN; META ANALYSIS; MORBIDITY; MORTALITY; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; REVIEW; SYMPATHETIC TONE; WELLBEING;

EID: 0030742493     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.00659.x     Document Type: Review

References (57)

1. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-1435.
2. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992; 20: 248-254.
3. Packer M. Pathophysiology of chronic heart failure. Lancet 1992; 340: 88-92.
4. Francis GS, Goldsmith SR, Olivari MT, Levine TB, Cohn JN. The neurohormonal axis in congestive heart failure. Ann Intern Med 1984; 101: 370-377.
5. Bristow MR, Hershberger RE, Port JD, et al. β-adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation 1990; 82 (Suppl I): 12-25.
6. Hasking GJ, Esler MD, Jennings GI, Burton D, Johns JA, Korner PI. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 1986; 73: 615-621.
7. Chidsey CA, Braunwald E, Morrow AG. Catecholamine excretion and cardiac stores of norepinephrine in congestive heart failure. Am J Med 1965; 39: 442-451.
8. Mann DL, Kent RL, Pardons B, Cooper IV. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 1992; 85: 790-804.
9. Hasenfuss G, Holubarsch C, Blanchard EM, et al. Influence of isoproterenol on myocardial energetics. Experimental and clinical investigations. Basic Research Cardiol 1989; 84 (Suppl 1): 147-155.
10. Meredith IT, Eisenhofer G, Lambert GW, Dewar EM, Jennings GI, Esler MD. Cardiac sympathetic nervous activity in congestive heart failure: evidence for increased neuronal norepinephrine release and preserved neuronal uptake. Circulation 1993; 88: 136-145.
11. Yates JC, Beamish RE, Dhalla NS. Ventricular dysfunction and necrosis produced by adrenochrome metabolite of epinephrine. Relation to pathogenesis of catecholamine cardiomyopathy. Am Heart J 1981; 102: 210-221.
12. The Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet 1990; 336: 1-6.
13. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic congestive heart failure. N Engl J Med 1991; 325: 1468-1475.
14. Packer M. Pathophysiological mechanisms underlying the effects of β-adrenergic agonists and antagonists on functional capacity and survival in chronic heart failure. Circulation 1990; 82 (Suppl I): 77-88.
15. Fowler MB, Laser JA, Hopkins GL, et al. Assessment of the β-adrenergic receptor pathway in the intact failing human heart: progressive receptor downregulation and subsensitivity to agonist response. Circulation 1986; 74: 1290-1302.
16. Fowler MB. Controlled trials with beta blockers in heart failure: metoprolol as the prototype. Am J Cardiol 1993; 71: 45C-53C.
17. Bristow MR, Larabee P, Muller-Beckmann, et al. Effect of carvedilol on adrenergic pharmacology in human ventricular myocardium and lymphocytes. Clin Invest 1992; 70: S105-S113.
18. Svedberg K. Initial experience with beta blockers in dilated cardiomyopathy. Am J Cardiol 1993; 71: 3OC-38C.
19. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beta adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975; 37: 1022-1026.
20. Svedberg K, Hjalmarson A, Waagstein F, Wallentin I. Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet 1979; i: 1374-1376.
21. Ikram H, Fitzpatrick D. Double-blind trial of chronic oral beta blockade in congestive cardiomyopathy. Lancet 1981; September 5; 490-493.
22. Currie PJ, Kelly MJ, McKenzie A, et al. Oral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy. J Am Coll Cardiol 1984; 3: 203-209.
23. Anderson JL, Lutz JR, Gilbert EM, et al. A randomized trial of low-dose beta blockade therapy for idiopathic dilated cardiomyopathy. Am J Cardiol 1985; 55: 471-475.
24. Engelmeier RS, O'Connell JB, Walsh R, et al. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation 1985; 72: 536-546.
25. Gilbert EM, Anderson JL, Deitchman D, et al. Long-term β-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med 1990; 88: 223-229.
26. Woodley SL, Gilbert EM, Anderson JL, et al. β-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation 1991; 84: 2426-2441.
27. Krum H, Sackner-Bernstein JD, Goldsmith R, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in severe chronic heart failure. Circulation 1995; 92: 1499-1506.
28. Metra M, Nardi M, Giubbini R, Del Cas L. Effects of short-and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994; 24: 1678-1687.
29. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomised study. J Am Coll Cardiol 1995; 25: 1225-1231.
30. Wisenbaugh T, Katz I, Davis J, et al. Long-term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol 1993; 21: 1094-1100.
31. Bristow MR, O'Connell JB, Gilbert EM, et al. Dose-response of chronic β-blocker treatment in heart failure from either idiopathic dilated or ischernic cardiomyopathy. Circulation 1994; 89: 1632-1642.
32. Krum H, Gu A, Wilshire-Clement M, et al. Changes in plasma endothelin-1 levels reflect clinical response to β-blockade in chronic heart failure. Am Heart J 1996; 131: 337-341.
33. Goldsmith RL, Krum H, Bigger JT Jr, Bloomfield D, Packer M. Beta-blockade increases parasympathetic activity in chronic heart failure. Circulation 1993; 88(suppl II): I-102. Abstract.
34. Waagstein F, Bristow MR, Svedberg K, et al. Beneficial effect of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993; 342: 1441-1446.
35. Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996; 94: 2800-2806.
36. Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. Circulation 1996; 94: 2793-2799.
37. Cohn JN, Fowler MB, Bristow MA, et al. Effect of carvedilol in severe chronic heart failure. J Am Coll Cardiol 1996; 27: 169A. Abstract.
38. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996; 94: 2807-2816.
39. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaernic heart disease. Lancet 1997; 349: 375-380.
40. Packer M, Rouleau J-L, Svedberg K, Pitt B, Fisher L, Klepper M and the PROFILE Investigators and Coordinators. Effect of flosequinan on survival in chronic heart failure: Preliminary results of the PROFILE Study. Circulation 1993; 88 (suppl I): I-301. Abstract.
41. Cohn JN, Levine B, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311: 819-823.
42. Francis GS, Cohn JN, Johnson G, et al. Plasma norepinephrine, plasma renin activity and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II follow-up. Circulation 1993; 87 (Suppl VI): VI-40-8.
43. CIBIS Investigators and Committees. A randomised trial of β-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994; 90: 1765-1773.
44. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Eng J Med 1996; 334: 1349-1355.
45. McMurray J, Hart W, Rhodes G. An evaluation of the cost of heart failure to the National Health Service in the UK. Br J Med Econ 1993; 6: 91-98.
46. Eichhorn EJ. The paradox of β-adrenergic blockade for the management of congestive heart failure. Am J Med 1992; 92: 527-538.
47. Kukin ML, Kalman J, Mannino M, Freudenberger R, Buchholz C, Ocampo O. Combined alpha-beta blockade (doxazosin plus metoprolol) compared with beta-blockade alone in chronic congestive heart failure. Am J Cardiol 1996; 77: 486-491.
48. Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996; 94: 2817-2825.
49. Chadda K, Goldstein, CK, Byington R, Curb JD. Effect of propranolol after acute myocardial infarction in patients with heart failure. Circulation 1986; 73: 503-510.
50. Ohlstein EH, Douglas SA, Sung CP, et al. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration and neointimal formation following vascular injury. Proc Natl Acad Sci USA 1993: 90: 6189-6193.
51. Yue T-L, Cheng H-Y, Lysko PG, et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992; 263: 92-98.
52. Sole MJ, Schimmer J, Golstein D, Li R-K. Oxidative stress contributes to decompensation of the failing heart. Circulation 1995; 92 (Suppl I): I-31 (Abstract).
53. Arleth AJ, Storer B, Romanic AM, Ohlstein EH. Carvedilol inhibits endothelin-1 biosynthesis in cultured human coronary artery endothelial cells. Circulation 1996; 94: I-401. Abstract.
54. Tsutamato T, Kanamori T, Kinoshita M. Plasma endothelin-1 concentration as a prognostic predictor in patients with heart failure. Circulation 1991; 84: II-470. Abstract.
55. Sackner-Bernstein J, Krum H, Goldsmith RL, et al. Should worsening heart failure early after initiation of beta-blocker therapy for chronic heart failure preclude long-term treatment? Circulation 1995; 92(suppl. I) I-395. Abstract.
56. Lechat P, Chalon S, Cucherat M, Packer M, Boissel JP. Meta-analysis of beta-blocker therapy in heart failure. Eur Heart J 1996; 17: 79. Abstract.
57. Cohn J. Preliminary results of the VEST trial. Presented at the 69th Scientific Session of the American Heart Association, 1996.